References
- Goto N, Tsurumi H, Takemura M, . Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. Leuk Lymphoma 2012;53:1494–1500.
- van Oers M, Pals S, Evers L, . Expression and release of CD27 in human B-cell malignancies. Blood 1993;82:3430–3436.
- Kok M, Bonfrer JM, Korse CM, . Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma. Tumour Biol 2003;24:53–60.
- Murase S, Saio M, Takenaka K, . Increased levels of CSF soluble CD27 in patients with primary central nervous system lymphoma. Cancer Lett 1998;132:181–186.
- Goto N, Tsurumi H, Takemura M, . Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma. Eur J Haematol 2006;77:217–225.
- Hintzen R, Lens S, Lammers K, . Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol 1995;154:2612–2623.
- Denoeud J, Moser M. Role of CD27/CD70 pathway of activation in immunity and tolerance. J Leukoc Biol 2011;89:195–203.
- Nolte MA, Van Olffen RW, Van Gisbergen KPJM, . Timing and tuning of CD27–CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev 2009;229:216–231.
- Dang LV, Nilsson A, Ingelman-Sundberg H, . Soluble CD27 induces IgG production through activation of antigen-primed B cells. J Intern Med 2011 Sep 14. [Epub ahead of print]
- Lens SMA, Drillenburg P, Den Drijver BFA, . Aberrant expression and reverse signalling of CD70 on malignant B cells. Br J Haematol 1999;106:491–503.
- Widney D, Gundapp G, Said JW, . Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol 1999;93:114–123.
- Akbar AN, Vukmanovic-Stejic M, Taams LS, . The dynamic co-evolution of memory and regulatory CD4 + T cells in the periphery. Nat Rev Immunol 2007;7:231–237.
- McEarchern JA, Smith LM, McDonagh CF, . Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res 2008;14:7763–7772.
- Israel BF, Gulley M, Elmore S, . Anti-CD70 antibodies: a potential treatment for EBV + CD70-expressing lymphomas. Mol Cancer Ther 2005;4:2037–2044.